Gamma-secretase is a fascinating multi-subunit intramembrane cleaving protease that is now being considered as a therapeutic target for a number of diseases. Primarily because gamma-secretase was a therapeutic target in Alzheimer's disease (AD), a number of GSIs have been developed that effectively inhibit gamma-secretase cleavage in humans. In humans with AD, long-term treatment with current GSIs appears to have mechanism based side-effects that limit the maximum tolerable dose to the point where the extent of long-term AB lowering is likely to be insufficient to have clinical impact in symptomatic patients. However, as elaborated on in Projects 1 and 2, because of its role in mediating signaling events from other proteins, with a primary focus on Notch signaling;gamma-secretase is a therapeutic target in cancer and immunologic disease and may very well be a target in other diseases, as long as the treatment window is acute, subacute or intermittent. Given the preliminary and published data in Projects 1 and 2 of this proposal as well as data from others supporting the repurposing of GSIs for multiple disease indications, further exploration of this ongoing repurposing effort is warranted. A major challenge when considering repurposing of GSIs is that the study of gamma-secretase cleavage has been dominated by its focus on APP and Notch 1. GSIs in AD are thought of as AB inhibitors and in cancer as Notch 1 inhibitors, but what about the GSI action on the nearly 100 additional substrates identified to date? Are these cleavages relevant or irrelevant to the biology of the system being investigated? Indeed, the major working hypothesis of this project is that in order to understand the biological role of gamma-secretase and appropriately repurpose GSIs for a given disease indication a fuller appreciation of gamma-secretase activity and the substrate inhibitory profiles of GSIs are needed. The studies proposed will enable facile assessment of cleavage of a broader repertoire of gamma-secretase substrates;guide the repurposing efforts for GSIs as therapeutics in cancer, GVHD and other emerging indications, and enable us to determine whether gamma-secretase cleavage is altered in aging or AD.
This research is relevant to public health as it will help insure that drugs (gamma-secretase inhibitors, GSIs) developed for use in Alzheimer's disease are optimally repurposed as therapeutics for cancer and immunologic diseases. Our research aligns with the NIH's mission by guiding further therapeutic development of drugs already tested in humans and thereby has the potential to reduce disease burden.
|Dawson, Ted M; Golde, Todd E; Lagier-Tourenne, Clotilde (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21:1370-1379|
|Hossain, Fokhrul; Sorrentino, Claudia; Ucar, Deniz A et al. (2018) Notch Signaling Regulates Mitochondrial Metabolism and NF-?B Activity in Triple-Negative Breast Cancer Cells via IKK?-Dependent Non-canonical Pathways. Front Oncol 8:575|
|Chandiran, Karthik; Lawlor, Rebecca; Pannuti, Antonio et al. (2018) Notch1 primes CD4 T cells for T helper type I differentiation through its early effects on miR-29. Mol Immunol 99:191-198|
|Hossain, Fokhrul; Majumder, Samarpan; Ucar, Deniz A et al. (2018) Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. Front Immunol 9:1288|
|Ran, Yong; Hossain, Fokhrul; Pannuti, Antonio et al. (2017) ?-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol Med 9:950-966|
|Sgolastra, Federica; Backlund, Coralie M; Ilker Ozay, E et al. (2017) Sequence segregation improves non-covalent protein delivery. J Control Release 254:131-136|
|Sarapas, Joel M; Backlund, Coralie M; deRonde, Brittany M et al. (2017) ROMP- and RAFT-Based Guanidinium-Containing Polymers as Scaffolds for Protein Mimic Synthesis. Chemistry 23:6858-6863|
|Aquila, Giorgio; Fortini, Cinzia; Pannuti, Antonio et al. (2017) Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: a pilot study. J Transl Med 15:98|
|Moyano, Daniel F; Liu, Yuanchang; Ayaz, Furkan et al. (2016) Immunomodulatory effects of coated gold nanoparticles in LPS-stimulated in vitro and in vivo murine model systems. Chem 1:320-327|
|Pannella, Micaela; Caliceti, Cristiana; Fortini, Francesca et al. (2016) Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells. J Cell Physiol 231:2700-10|
Showing the most recent 10 out of 37 publications